In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Cost-Sharing Solution: The New NICE Ticket

Executive Summary

J&J's Velcade and Celgene's Revlimid illustrate how pharma has adapted to the NICE UK cost-effectiveness watchdog. Now that the UK precedents exist, there will be more to come. But are they really pharma's ticket to increased access, and do they assure the value to the health care system that they claim? This article originally appeared in February 2009's RPM Report.

You may also be interested in...



Rising Payor Influence Means Successful Drug Launches are Rarer

Growing payor influence on the uptake of high-price products is making successful drug launches far harder to achieve. Payor power varies from one Western market to the next, but all are moving in the same direction, with weakening prescriber clout and thus also less impact from detailing on launch success.

Rising Payor Influence Means Successful Drug Launches are Rarer

Growing payor influence on the uptake of high-price products is making successful drug launches far harder to achieve. Payor power varies from one Western market to the next, but all are moving in the same direction, with weakening prescriber clout and thus also less impact from detailing on launch success.

U.K. NICE Snubs Novo's Victoza, But Drug Launches Fast In The U.S.

The U.K.'s cost-effectiveness watchdog, the National Institute of Clinical Excellence, issued draft guidance on Feb. 15 recommending only limited reimbursement for Novo Nordisk's newly-launched diabetes drug Victoza (liraglutide), despite the GLP-1 analog's proven efficacy not only in lowering blood sugar, but also in promoting weight loss

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC100339

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel